Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on Agenus and keeping the price target at $23.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Emily Bodnar’s rating is based on Agenus’ strengthening clinical profile for bot/bal and its growing momentum toward potential registration. She highlights that the therapy now has data from more than 1,200 patients across nine tumor types, including encouraging survival outcomes in metastatic colorectal cancer where existing immunotherapies have limited impact, and notes that these maturing results may support future regulatory discussions and possible accelerated pathways.
She also emphasizes the company’s improving financial position and disciplined cost structure, supported by early-access revenues and the recent Zydus transaction that lifted pro-forma cash to roughly $100.7M. In her view, the collaboration-led Phase 3 BATTMAN trial should be more cost-efficient than a traditional large registration study, while real-world use through French AAC and NPP programs simultaneously generates cash, builds physician familiarity, and strengthens the eventual commercial and payer case for bot/bal.
Bodnar covers the Healthcare sector, focusing on stocks such as NovoCure, Agenus, and Acrivon Therapeutics, Inc.. According to TipRanks, Bodnar has an average return of 5.6% and a 33.68% success rate on recommended stocks.